Therefore, investigating the downstream mechanisms of AMPK regulation in hepatic lipid metabolism can provide theoretical basis for MASLD treatment through targeted AMPK activation, but may not explain the pathogenesis of MASLD. Here, PRKAB1 is linked to metabolic dysfunction-associated steatotic liver disease.